Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Highly prestigious award endowed with €500,000 to uphold the United Nations 2030 Agenda
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
BVX-0922 to target colorectal cancer under investigator-sponsored IND
New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
Launched in the year 2018, MedEngage Scholarship Program is aimed at nurturing and nourishing medical talent in India
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Cabenuva was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's decades-long commitment to combatting HIV
Recommendation is based on pivotal data from the phase III POLARIX study
Subscribe To Our Newsletter & Stay Updated
